Leukemia

The anti–PD-1 (programmed death 1) antibody nivolumab has shown activity in patients with hematologic cancers who have failed three or more prior therapies.

The anti-PD-1 drug pembrolizumab demonstrated promising anti-tumor activity in patients with heavily pretreated classic Hodgkin lymphoma.

Sorafenib proved to have a high level of efficacy in younger acute myeloid leukemia patients, improving both event- and relapse-free survival over placebo.

T-lymphoblastic leukemia (T-ALL) should no longer be considered a poor-risk disease in the pediatric population, according to data presented at ASH.

The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.

Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.

Adding the HDAC inhibitor valproic acid to decitabine did not improve outcomes in patients with myelodysplastic syndromes or acute myeloid leukemia.

Hispanic childhood cancer survivors are less likely to receive follow-up care later in life than white survivors, according to a new study.

Survivors of childhood Hodgkin lymphoma who went on to regularly complete vigorous exercise had a lower risk of cardiovascular events later in life.

Ninety percent of patients with relapsed/refractory acute lymphoblastic leukemia achieved complete remission after a T-cell therapy treatment targeting CD19.

Monitoring minimal residual disease and real-time quantitative polymerase chain reaction can predict relapse in pediatric acute lymphoblastic leukemia patients.

A phase III trial of vosaroxin failed to meet its primary overall survival endpoint in patients with first relapsed or refractory acute myeloid leukemia.

In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.

A regimen of gemcitabine/dexamethasone/cisplatin was as effective and less toxic than the current standard of care for treating relapsed, refractory lymphoma.

Patients with non-high-risk APL can achieve better clinical outcomes when treated with ATRA plus arsenic trioxide compared with ATRA plus chemotherapy, a new study found.

Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy have an increased risk of developing diabetes mellitus, says a new study.

A study of more than 4,500 patients with acute myeloid leukemia (AML) found that predicting resistance to therapy remains an elusive practice.

STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.

A laboratory study found that natural killer cells could be multiplied from the blood of patients to fight off precursor B-lineage acute lymphoblastic leukemia.

Survivors of Hodgkin lymphoma may be at increased risk of diabetes if they were exposed to radiation to the para-aortic lymph nodes and spleen during treatment.

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.

The addition of gemtuzumab-ozogamicin to standard chemo improved event-free survival in children and young adults with newly diagnosed acute myeloid leukemia.

Patients with pediatric BCR-ABL1-like acute lymphoblastic leukemia should be given risk-directed therapy based on minimal residual disease levels, according to a new study.

The FDA approved idelalisib (Zydelig) yesterday for the treatment of relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL).

Rapidly generated virus-specific T cells (VSTs) were safe and effective against five infections that commonly affect immunocompromised patients after marrow or stem cell transplantation, according to a new small study.